The Development of Pharmacological Therapies for Alzheimer’s Disease

被引:0
|
作者
Ping Lin
Junyu Sun
Qi Cheng
Yue Yang
Dennis Cordato
Jianqun Gao
机构
[1] Shanghai Mental Health Center,Department of Medical Laboratory
[2] Shanghai Jiao Tong University School of Medicine,Department of Psychosis, Institute of Psychiatry, Psychology and Neuroscience
[3] King’s College London,Department of Neurology and Neurophysiology
[4] Liverpool Hospital,Stroke and Neurology Research Group
[5] Ingham Institute for Applied Medical Research,Brain and Mind Centre, Central Clinical School
[6] the University of Sydney,undefined
来源
Neurology and Therapy | 2021年 / 10卷
关键词
Alzheimer’s disease; Disease-modifying therapy; Symptomatic treatment; Clinical trial;
D O I
暂无
中图分类号
学科分类号
摘要
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that currently has no cure. The aged population is growing globally, creating an urgent need for more promising therapies for this debilitating disease. Much effort has been made in recent decades, and the field is highly dynamic, with numerous trials. The main focus of these trials includes disease modification and symptomatic treatment. Some have shown beneficial outcomes, while others have shown no significant benefits. Here, we cover the outcome of recently published AD clinical trials, as well as the mechanism of action of these therapeutical agents, to re-think drug development strategies and directions for future studies.
引用
收藏
页码:609 / 626
页数:17
相关论文
共 50 条
  • [21] Pharmacological treatment of Alzheimer’s Disease
    Angelo Bianchetti
    Piera Ranieri
    Alessandro Margiotta
    Marco Trabucchi
    Aging Clinical and Experimental Research, 2006, 18 : 158 - 162
  • [22] The pharmacological management of Alzheimer's disease
    Bishara, Delia
    Sauer, Justin
    Taylor, David
    PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2015, 19 (04) : 9 - 16
  • [23] The pharmacological management of Alzheimer's disease
    Bishara, Delia
    PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2010, 14 (01) : 16 - 22
  • [24] Preclinical and clinical challenges in the development of disease-modifying therapies for Alzheimer's disease
    Scorer, CA
    DRUG DISCOVERY TODAY, 2001, 6 (23) : 1207 - 1219
  • [25] Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies
    Golde, Todd E.
    JOURNAL OF NEUROCHEMISTRY, 2016, 139 : 224 - 236
  • [26] Disease-modifying therapies in Alzheimer's disease
    Salloway, Stephen
    Mintzer, Jacobo
    Weiner, Myron F.
    Cummings, Jeffrey L.
    ALZHEIMERS & DEMENTIA, 2008, 4 (02) : 65 - 79
  • [27] Alzheimer's disease: understanding homeostasis deregulation to foster development of effective therapies
    Nistico, Robert
    Peineau, Stephane
    PHARMACOLOGICAL RESEARCH, 2019, 139 : 467 - 468
  • [28] Animal models in the development of symptomatic and preventive drug therapies for Alzheimer's disease
    Riekkinen, P
    Schmidt, BH
    van der Staay, FJ
    ANNALS OF MEDICINE, 1998, 30 (06) : 566 - 576
  • [29] Alzheimer's Disease: Combination Therapies and Clinical Trials for Combination Therapy Development
    Cummings, Jeffrey L.
    Osse, Amanda M. Leisgang
    Kinney, Jefferson W.
    Cammann, Davis
    Chen, Jingchun
    CNS DRUGS, 2024, 38 (08) : 613 - 624
  • [30] Alzheimer's and Parkinson's disease therapies in the clinic
    Chopade, Puja
    Chopade, Neha
    Zhao, Zongmin
    Mitragotri, Samir
    Liao, Rick
    Suja, Vineeth Chandran
    BIOENGINEERING & TRANSLATIONAL MEDICINE, 2023, 8 (01)